Creabilis adds three executives to management team
Reflects growing confidence in pipeline and science that underpins it
Alex Leech joins as vice president, head of finance and operations, James Sandy as senior vice president, head of development, and Peter Spargo as senior vice president for chemistry manufacturing and controls (CMC).
Leech was most recently head of operations at Solace Pharmaceuticals. Prior to this, he worked for the Pfizer r&d organisation where he was head of European project management. He has also held a number of operational and engineering management roles at Ford. Sandy was most recently at Pfizer as development team leader of Pfizer’s GI portfolio. Prior to working at Pfizer, he was head of biometrics at Astra UK.
Spargo was most recently at Novexel as senior vice president of CMC. Prior to this he was head of chemical process r&d for Pfizer in Europe.
Eliot Forster, ceo of Creabilis, said: ‘This expansion of our senior management team reflects Creabilis’ growing maturity and the confidence we have in our pipeline, our science and the culture that underpins it.’
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development
Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme
The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development
Research & Development
Leinco Technologies and CellCarta partner to advance proteomics solutions for discovery and drug development
The pair have announced a strategic collaboration combining Leinco's IHC and spatial biology-validated antibody portfolio with CellCarta's CPTAC-validated Immuno-MRM assay resources to enhance proteomic analysis for immuno-oncology and targeted therapy development
Research & Development
Biognosys collaborates with Michael J. Fox Foundation to develop biomarker assays for Parkinson's research
The pair will work to develop highly sensitive, quantitative biomarker assays targeting LRRK2, the most common genetic risk factor for late-onset Parkinson's disease, in support of the foundation's global LITE initiative spanning more than 50 academic, industry and clinical partners